Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641259 | 0.98 | CA2 (0.39) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| SCHEMBL29561231 | 0.98 | CA2 (0.39) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| Bromide SCHEMBL11435482 | 0.96 | CA2 (0.38) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| Bromide SCHEMBL10844297 | 0.79 | CA2 (0.35) | SMN1; SMN2LMNACA2TP53TAAR1 | |
| Hydrochloric Acid SCHEMBL11428178 | 0.76 | LPL (0.35) | SMN1; SMN2CA2TP53TAAR1CYP2A6 | |
| SCHEMBL8723606 | 0.76 | KDM4E (0.36) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| Iodide SCHEMBL3862124 | 0.76 | CA2 (0.39) | SMN1; SMN2LMNACA2TP53TAAR1 | |
| SCHEMBL1105765 | 0.75 | LMNA (0.43) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| Iodide SCHEMBL3317180 | 0.74 | CA2 (0.42) | SMN1; SMN2LMNACA2TP53TAAR1 | |
| Bromide SCHEMBL10858949 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629491-B2 | Hydrocarboxylation process | EASTMAN CHEMICAL COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-20070299280-A1 | forming propionic acid from ethylene, water and carbon monoxide; not using the hazardous and corrosive hydrogen halides or sulfonic acids; free of hydrogen iodide and/or ethyl iodide; no diethyl ketone by-products | EASTMAN CHEMICAL COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299280-A1 | forming propionic acid from ethylene, water and carbon monoxide; not using the hazardous and corrosive hydrogen halides or sulfonic acids; free of hydrogen iodide and/or ethyl iodide; no diethyl ketone by-products | ETV6, ETV1, HAO2 | SMN1; SMN2 3854/4885LMNA 4077/4885KDM4E 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.